Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Entrada Therapeutics Inc's Business Segments
Entrada Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 1
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 1 | 100% |
Description of Entrada Therapeutics Inc
Entrada Therapeutics Inc is a clinical-stage biotechnology company that is dedicated to developing transformative therapeutics for various serious diseases. The company's technology platform is focused on utilizing the body's natural cellular uptake mechanisms to deliver large macromolecules, such as proteins and nucleic acids, across biological barriers for targeted intracellular delivery.
Founded in 2018, Entrada Therapeutics is headquartered in Boston, Massachusetts, in the United States, with additional offices in San Diego, California. The company is led by a team of seasoned industry executives, including CEO Dipal Doshi, President and COO Meghna Dasgupta, and CMO James Hamilton.
The company's lead program, ENTR-101, is a potential treatment for cystic fibrosis. ENTR-101 utilizes Entrada's proprietary Endosomal Escape Vehicle (EEV) technology to transport a specially designed protein that corrects the underlying genetic mutation causing cystic fibrosis. This technology allows the protein to enter the cell, bypass molecular barriers and reach its target in the endosome, thus enabling the protein to be fully functional.
In addition to ENTR-101, Entrada has a robust pipeline that includes multiple therapeutic programs in various stages of development. The company is focused on developing therapies for indications where macromolecular therapeutics have the potential to provide significant patient benefit, such as neurodegenerative diseases, genetic disorders, and cancer.
Entrada Therapeutics has developed strategic collaborations with key partners in the biotech industry, including Roche, Ferring Pharmaceuticals, and BMS. These partnerships provide the company with additional funding and resources, as well as important guidance and expertise.
Overall, Entrada Therapeutics is committed to bringing innovative, life-changing therapies to patients in need, by harnessing the power of its unique technology platform and scientific expertise. Their work is poised to have a profound impact on the lives of patients suffering from serious diseases.
Founded in 2018, Entrada Therapeutics is headquartered in Boston, Massachusetts, in the United States, with additional offices in San Diego, California. The company is led by a team of seasoned industry executives, including CEO Dipal Doshi, President and COO Meghna Dasgupta, and CMO James Hamilton.
The company's lead program, ENTR-101, is a potential treatment for cystic fibrosis. ENTR-101 utilizes Entrada's proprietary Endosomal Escape Vehicle (EEV) technology to transport a specially designed protein that corrects the underlying genetic mutation causing cystic fibrosis. This technology allows the protein to enter the cell, bypass molecular barriers and reach its target in the endosome, thus enabling the protein to be fully functional.
In addition to ENTR-101, Entrada has a robust pipeline that includes multiple therapeutic programs in various stages of development. The company is focused on developing therapies for indications where macromolecular therapeutics have the potential to provide significant patient benefit, such as neurodegenerative diseases, genetic disorders, and cancer.
Entrada Therapeutics has developed strategic collaborations with key partners in the biotech industry, including Roche, Ferring Pharmaceuticals, and BMS. These partnerships provide the company with additional funding and resources, as well as important guidance and expertise.
Overall, Entrada Therapeutics is committed to bringing innovative, life-changing therapies to patients in need, by harnessing the power of its unique technology platform and scientific expertise. Their work is poised to have a profound impact on the lives of patients suffering from serious diseases.
Entrada Therapeutics Inc: Overview
Entrada Therapeutics Inc is a cutting-edge biotechnology company that specializes in developing innovative therapeutics to address challenging medical conditions, particularly rare and serious diseases. At the heart of its mission is a commitment to enhancing therapeutic delivery, leveraging its proprietary technology known as intracellular biologics. This platform is designed to overcome traditional barriers in drug delivery, enabling more effective treatment of diseases at the cellular level.
Segments
Entrada Therapeutics operates within the healthcare industry, specifically in the biotechnology sector. The companys primary focus is the development of therapeutics that address rare diseases and various serious medical conditions. The emphasis on rare diseases is critical, as these conditions often lack effective treatments due to the complexities involved in drug development and delivery.
Products
Entradas proprietary intracellular biologics platform enables the design of various therapeutic products that utilize innovative delivery mechanisms. The following are key products in development:
1. ENTR-501:
- Description: ENTR-501 is a biologic enzyme replacement therapy specifically targeting lysosomal storage disorders (LSDs). These disorders arise due to deficiencies in specific enzymes that are crucial for the breakdown of biomolecules within lysosomes.
- Mechanism of Action: By delivering therapeutic enzymes directly to the lysosomes, ENTR-501 aims to restore normal cellular function and alleviate symptoms associated with enzyme deficiency.
- Development Stage: Currently in preclinical development, with ongoing studies to evaluate its efficacy and safety in relevant disease models.
2. ENTR-201:
- Description: ENTR-201 targets genetic disorders affecting the liver, such as alpha-1-antitrypsin (AAT) deficiency, which can lead to severe lung and liver diseases due to protein misfolding and accumulation.
- Mechanism of Action: This biologic therapy is designed to be absorbed by liver cells and release therapeutic molecules that interact with specific receptors, facilitating the necessary treatment of the hepatic condition.
- Development Stage: Also in preclinical development, ENTR-201 is undergoing testing to validate its therapeutic potential for liver-related genetic disorders.
3. ENTR-702:
- Description: Aimed at addressing neurodegenerative conditions, ENTR-702 focuses on treating diseases like Parkinsons and Alzheimers by utilizing the intracellular biologics platform.
- Mechanism of Action: This products novel approach involves crossing the blood-brain barrier to deliver therapeutic molecules directly to the brain, targeting the underlying pathophysiology of these debilitating diseases.
- Development Stage: Currently in preclinical development, with research efforts directed at establishing its effectiveness in models of neurodegeneration.
Services
While Entrada Therapeutics Inc does not provide direct services, it engages in collaborative partnerships and initiatives essential for advancing its product development. The company works alongside a variety of stakeholders, including:
- Academic Institutions: Collaborations with researchers and academic bodies to leverage collective expertise in biotechnology and therapeutic discovery.
- Biotechnology and Pharmaceutical Companies: Strategic partnerships with other organizations to enhance research capabilities and resource sharing, optimizing the drug development process.
- Patients, Clinicians, and Advocacy Groups: Engaging with these communities ensures that the development of Entrada’s therapeutics addresses pressing unmet medical needs, particularly for patients suffering from rare and serious diseases.
Summary
Entrada Therapeutics Inc stands at the forefront of biotechnology innovation, utilizing its proprietary intracellular biologics platform to develop targeted therapeutics for rare and serious diseases. With a promising pipeline that includes enzyme replacement therapies and molecules capable of crossing biological barriers, the company is dedicated to transforming treatment paradigms and improving patient outcomes in challenging therapeutic areas. Through collaborations and partnerships, Entrada remains committed to addressing critical needs within the healthcare landscape.
Entrada Therapeutics Inc is a cutting-edge biotechnology company that specializes in developing innovative therapeutics to address challenging medical conditions, particularly rare and serious diseases. At the heart of its mission is a commitment to enhancing therapeutic delivery, leveraging its proprietary technology known as intracellular biologics. This platform is designed to overcome traditional barriers in drug delivery, enabling more effective treatment of diseases at the cellular level.
Segments
Entrada Therapeutics operates within the healthcare industry, specifically in the biotechnology sector. The companys primary focus is the development of therapeutics that address rare diseases and various serious medical conditions. The emphasis on rare diseases is critical, as these conditions often lack effective treatments due to the complexities involved in drug development and delivery.
Products
Entradas proprietary intracellular biologics platform enables the design of various therapeutic products that utilize innovative delivery mechanisms. The following are key products in development:
1. ENTR-501:
- Description: ENTR-501 is a biologic enzyme replacement therapy specifically targeting lysosomal storage disorders (LSDs). These disorders arise due to deficiencies in specific enzymes that are crucial for the breakdown of biomolecules within lysosomes.
- Mechanism of Action: By delivering therapeutic enzymes directly to the lysosomes, ENTR-501 aims to restore normal cellular function and alleviate symptoms associated with enzyme deficiency.
- Development Stage: Currently in preclinical development, with ongoing studies to evaluate its efficacy and safety in relevant disease models.
2. ENTR-201:
- Description: ENTR-201 targets genetic disorders affecting the liver, such as alpha-1-antitrypsin (AAT) deficiency, which can lead to severe lung and liver diseases due to protein misfolding and accumulation.
- Mechanism of Action: This biologic therapy is designed to be absorbed by liver cells and release therapeutic molecules that interact with specific receptors, facilitating the necessary treatment of the hepatic condition.
- Development Stage: Also in preclinical development, ENTR-201 is undergoing testing to validate its therapeutic potential for liver-related genetic disorders.
3. ENTR-702:
- Description: Aimed at addressing neurodegenerative conditions, ENTR-702 focuses on treating diseases like Parkinsons and Alzheimers by utilizing the intracellular biologics platform.
- Mechanism of Action: This products novel approach involves crossing the blood-brain barrier to deliver therapeutic molecules directly to the brain, targeting the underlying pathophysiology of these debilitating diseases.
- Development Stage: Currently in preclinical development, with research efforts directed at establishing its effectiveness in models of neurodegeneration.
Services
While Entrada Therapeutics Inc does not provide direct services, it engages in collaborative partnerships and initiatives essential for advancing its product development. The company works alongside a variety of stakeholders, including:
- Academic Institutions: Collaborations with researchers and academic bodies to leverage collective expertise in biotechnology and therapeutic discovery.
- Biotechnology and Pharmaceutical Companies: Strategic partnerships with other organizations to enhance research capabilities and resource sharing, optimizing the drug development process.
- Patients, Clinicians, and Advocacy Groups: Engaging with these communities ensures that the development of Entrada’s therapeutics addresses pressing unmet medical needs, particularly for patients suffering from rare and serious diseases.
Summary
Entrada Therapeutics Inc stands at the forefront of biotechnology innovation, utilizing its proprietary intracellular biologics platform to develop targeted therapeutics for rare and serious diseases. With a promising pipeline that includes enzyme replacement therapies and molecules capable of crossing biological barriers, the company is dedicated to transforming treatment paradigms and improving patient outcomes in challenging therapeutic areas. Through collaborations and partnerships, Entrada remains committed to addressing critical needs within the healthcare landscape.